louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06188767: Testosterone-induced Muscle Memory and Underlying Mechanisms
Official title: Long-term Effects of Anabolic Androgenic Steroids on Muscle Growth Potential: Testosterone-induced Muscle Memory and Underlying Mechanisms
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Skeletal Muscle Physiology
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
First posted: 2024-01-03
Enrollment: 30
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this project is to investigate underlying mechanisms of testosterone- and resistance training-induced muscle hypertrophy and muscle memory in humans.


Eligibility criteria: Inclusion Criteria:

* Healthy men and women
* BMI of \<26 and normal ECG and blood pressure

Exclusion Criteria:

* Smoking
* Chronic disease,
* Use of prescription medication
* Pain due to current or previous musculoskeletal injury
* Resistance training more than once per week in the 12 months leading up to the intervention
* Current or previous use of prohibited anabolic substances

Primary outcomes:
measure: Fiber cross-sectional area
timeFrame: The change in fiber cross-sectional is assessed at baseline, 4, 20 and 24 weeks
measure: Myonuclei
timeFrame: The change in myonuclei is assessed at baseline, 4, 20 and 24 weeks
measure: Skeletal muscle proteome
timeFrame: The change in the muscle proteome is assessed at baseline, 4, 20 and 24 weeks
Secondary outcomes:
measure: Lean mass
timeFrame: The change in lean mass is assessed at baseline, 4, 20 and 24 weeks
measure: Satellite cells
timeFrame: The change in satellite cells is assessed at baseline, 4, 20 and 24 weeks
measure: Muscle strength
timeFrame: The change in 1-repetition maximum is assessed at baseline, 4, 20 and 24 weeks
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, University of Copenhagen
Study officials:
References:
Clinical trial NCT00013767: Community Based Prevention/Control Project
Official title: Child Environmental Health Center--Reducing Pesticide Exposure in Children of Farmworkers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Poisoning
Keywords: Pesticide
Insecticide
Organophosphate
Child Health
Exposure Prevention
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS)
Sponsor class: NIH
Collaborators: name: Environmental Protection Agency (EPA)
First posted: 2001-03-30
Enrollment: 400
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Primary purpose: PREVENTION

Brief summary: This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. The project will develop and implement a community-wide intervention to reduce the transfer of pesticides from the workplace to the home (take home pathway).

Detailed description: This project is aimed at better understanding how children living in agricultural environments are exposed to pesticides, and how such exposures can be prevented or reduced. Since 1991 our group has investigated pesticide expsoures among children of agricultural families in Washington state, focusing on exposure to organophosphate insecticides. We have demonstrated in these studies that the residential environments of agricultural families have higher pesticide residues than do other homes in this region. We have also found that children living in these residential environments have elevated levels of pesticide metabolites in their urine. We need to better understand how these children are being exposed in order to develop recomendations for exposure prevention or reduction. The current project will develop and implement a community-wide intervention to reduce the transfer of pesticides from the workplace to the home (take home pathway). A complementary project is also underway by the UW-Child Health Center to characterize pesticide exposure pathways for children of farmworkers.

Eligibility criteria: Each family recruited must include one child between the ages of 1-5. Recruitment will be confined to the lower Yakima Valley.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03622567: The Effect of Smartphone Push Notifications on Brain Power Score
Official title: Assessing the Effect of Smartphone Push Notifications on Overall Score, Accuracy and Reaction Time of Brain Power Score
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Lead sponsor: HealthTech Connex Inc.
Sponsor class: INDUSTRY
First posted: 2018-08-09
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study will examine how Brain Power Score, an objective measure of brain function, is affected by the presence of smartphone push notifications.

Detailed description: Smartphones are a common device integrated into the lives of many individuals around the world. Researchers have previously found a relationship between mobile phone use and changes in brain activity, reaction times and sleep patterns.

Brain Power is a consumer-grade application using a proprietary combination of neurological (EEG) and behavioral (reaction time and accuracy) data to create a comprehensive score out of 1000 which allows users to have an objective evaluation of their brain performance.

This study will examine how Brain Power Score is affected by the presence of smartphone push notifications.

Eligibility criteria: Inclusion Criteria:

* Healthy volunteers
* ≥19 years old
* Must be proficient in English
* Must be able to understand the study procedure and give informed consent

Exclusion Criteria:

* Unable to provide informed consent

Primary outcomes:
measure: Total Brain Power Score
timeFrame: 20 minutes
Secondary outcomes:
measure: Accuracy
timeFrame: 20 minutes
measure: Reaction time
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Surrey
country: Canada
facility: HealthTech Connex Centre for Neurology Studies
state: British Columbia
Study officials:
References:
Clinical trial NCT02414867: Total Energy Expenditure and Fat Oxidation in 2 Year Old Children
Official title: Total Energy Expenditure and Fat Oxidation in 2 Year Old Children
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2015-04-13
Enrollment: 16
Sex: ALL
Minimum age (years): 2
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 120 toddlers born from mothers of the Glowing study (NCT01131117)

Brief summary: The purpose of the study is to determine energy expenditure and fat oxidation in 2 year old children.


Eligibility criteria: Inclusion Criteria:

* 1.5-2.5 years of age
* Mother is a participant of the Glowing study (NCT01131117)
* Healthy without taking medication that can affect study outcomes, as determined by the PI

Exclusion Criteria:

* None listed

Primary outcomes:
measure: To determine total energy expenditure in 2 year old children
timeFrame: 15 days
measure: To determine fat oxidation in 2 year old children
timeFrame: 2-6 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
affiliation: Arkansas Children's Nutrition Center
name: Elisabet Borsheim, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02971267: Follow-up of the Cardiomyopathy Cohort SFB/TR19
Official title: Follow-up of the Inflammatory Cardiomyopathy Cohort of SFB/TR19
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiomyopathies
Heart Failure
Keywords: heart failure
cardiomyopathy
myocarditis
Lead sponsor: University Medicine Greifswald
Sponsor class: OTHER
First posted: 2016-11-22
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with suspected or validated inflammatory cardiomyopathy at baseline

Brief summary: Follow-up of a cohort of inflammatory cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB-TR19 project. Standardized protocols will be used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biomaterials for biobanking purposes.

Detailed description: Periodical follow-up of a cohort of inflammatory cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the SFB/TR19 project. Participants will be followed up at least every year - or more frequently based on clinical need. Standardized protocols will be used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biomaterials for biobanking purposes.

Eligibility criteria: Inclusion Criteria:

* Participation in baseline examination of SFB/TR19

Exclusion Criteria:

* none

Primary outcomes:
measure: Number of cardiovascular events
timeFrame: 1-year follow-ups up to 10 years
Secondary outcomes:
measure: LVEF (left ventricular ejection fraction)
timeFrame: 1-year follow-ups up to 10 years
measure: VO2peak
timeFrame: 1-year follow-ups up to 10 years
measure: QOL
timeFrame: 1-year follow-ups up to 10 years
measure: Mortality
timeFrame: 1-year follow-ups up to 10 years
Other outcomes:
Locations:
city: Greifswald
country: Germany
facility: Department of Internal Medicine B, University Medicine Greifswald
state: MV
Study officials:
References:
Clinical trial NCT04201067: Large-Scale Metabolomic Profiling for the Diagnosis of Inborn Errors of Metabolism
Official title: Large-Scale Metabolomic Profiling for the Diagnosis of Inborn Errors of Metabolism
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Congenital Disorders of Glycosylation
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Institute of Neurological Disorders and Stroke (NINDS)
First posted: 2019-12-17
Enrollment: 510
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: These individuals will likely have a congenital disorder of glycosylation or other metabolic disease.

Brief summary: Researchers are trying to determine the efficacy of a global metabolomic approach in testing for and diagnosing inborn errors of metabolism as opposed to traditional testing methods.

Detailed description: Residual samples will be tested for a variety of biomarkers that may lead to better understanding of these disorders and help develop treatment options.

Eligibility criteria: Inclusion Criteria:

* All individuals with specimens in Biochemical Genetics Laboratory and from patients collected under another IRB who have agreed to share samples/data

Exclusion Criteria:

* None

Primary outcomes:
measure: Quantify N-linked glycan intermediates in plasma and urine
timeFrame: length of study, up to 5 years
measure: Develop quantitative biomarkers for PGM1-CDG patients to monitor the efficacy of galactose therapy.
timeFrame: length of study, up to 5 years
measure: Develop quantitative biomarkers for SLC35A2-CDG patients and monitor galactose therapy efficacy.
timeFrame: length of study, up to 5 years
measure: Validate biomarker to diagnose and follow NGLY1 deficiency and monitor N-acetylglucosamine (GlcNAc) therapy response.
timeFrame: length of study, up to 5 years
measure: Validate novel diagnostic biomarkers for ALG13-CDG
timeFrame: length of study, up to 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: David Deyle, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06516367: Screening Tool for Malnutrition, Sarcopenia, and Cachexia
Official title: Development and Validation of a New Tool for Simultaneous Screening of Malnutrition, Sarcopenia, and Cachexia in Older Adults
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Malnutrition
Sarcopenia
Cachexia
Keywords: screening
older adult
malnutrition
cachexia
sarcopenia
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2024-07-23
Enrollment: 300
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 300 older participants aged 60 years old and above who were admitted to Ain Shams University Hospitals or interviewed at the hospital clinic

Brief summary: There is an accumulating evidence of the overlap and frequent co-occurrence of twasting conditions in older adults. Those conditions include malnutrition, sarcopenia, and cachexia, Therefore , a tool capable of simultaneously screening for all three conditions is imperative. In this study, we developed and validated a new tool for the simultaneous screening of muscle wasting diseases in older adults. The diagnostic accuracy of the new tool was compared to other validated screening tools including the Mini Nutritional Assessment-Short Form (MNA-SF), the Short Nutritional Assessment Questionnaire (SNAQ), and the Simple Questionnaire to Rapidly Diagnose Sarcopenia (SARC-F).


Eligibility criteria: Inclusion Criteria:

* Participants Aged 65 years and older, who agree to participate

Exclusion Criteria:

* Patients with critical illness.
* Patients with severe cognitive, hearing or visual impairment hindering proper communication
* Patients with physical disability that interfere with physical performance assessment or hand grip measurement
* Patient with any contraindication of to the use of BIA) e.g. presence of a pacemaker, other implanted electrical devices, or metal implants, volume overload

Primary outcomes:
measure: reliability of a new tool for the simultaneous screening of muscle wasting diseases in older adults
timeFrame: 10 months
measure: validity of a new tool for the simultaneous screening of muscle wasting diseases in older adults
timeFrame: 10 months
Secondary outcomes:
measure: The diagnostic accuracy of the new tool
timeFrame: 10 months
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University
Study officials:
References:
Clinical trial NCT02654067: Evaluation of Mallampati Score Changes in Pregnancy
Official title: Evaluation of Mallampati Score Changes in Pregnancy
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Pregnancy
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2016-01-13
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant patients

Brief summary: Pregnant patients mallampati class scores will be examined throughout pregnancy

Detailed description: Photographs of the airway will be taken and compared throughout labor and delivery

Eligibility criteria: Inclusion Criteria:

* pregnant
* at least 18 years of age

Exclusion Criteria:

* refusal of consent
* known difficult airway

Primary outcomes:
measure: Mallampati score changes during pregnancy
timeFrame: 40 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Julian Robinson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mallampati SR, Gatt SP, Gugino LD, Desai SP, Waraksa B, Freiberger D, Liu PL. A clinical sign to predict difficult tracheal intubation: a prospective study. Can Anaesth Soc J. 1985 Jul;32(4):429-34. doi: 10.1007/BF03011357.
citation: Kodali BS, Chandrasekhar S, Bulich LN, Topulos GP, Datta S. Airway changes during labor and delivery. Anesthesiology. 2008 Mar;108(3):357-62. doi: 10.1097/ALN.0b013e31816452d3.
citation: Pilkington S, Carli F, Dakin MJ, Romney M, De Witt KA, Dore CJ, Cormack RS. Increase in Mallampati score during pregnancy. Br J Anaesth. 1995 Jun;74(6):638-42. doi: 10.1093/bja/74.6.638.
Clinical trial NCT02732067: Death Rate in Anesthesia, a Study in a Tertiary Hospital
Official title: Death Rate in Anesthesia: a Prospective Study of Two Years Period From a Tertiary Hospital
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sudden Death
Keywords: Anesthesia
Lead sponsor: University of Jordan
Sponsor class: OTHER
First posted: 2016-04-08
Enrollment: 30
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent anesthesia and surgery and died inside the hospital

Brief summary: Death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients.

In this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018.

Detailed description: Death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. Most of the studies of death rate in anesthesia are retrospective with many drawbacks and pitfalls like absence of information in the records of the patients.

In this study, the investigators will follow the death among patients who underwent surgery under anesthesia whether regional or general over the next two years from 2016 to 2018, by examining the patients records from the hospital database and recording the events that occur to the dead patients.

The end point of this study will be anesthesia death rate inside the hospital.

Eligibility criteria: Inclusion Criteria:

* Patients who underwent anesthesia and surgery.
* Patients who died inside the hospital.

Exclusion Criteria:

* Patient who underwent anesthesia and surgery and do not died and discharged home.
* Patients who died outside the hospital.

Primary outcomes:
measure: number of anesthetized patients who died in the perioperative period inside the hospital
timeFrame: 30 days post-operative
Secondary outcomes:
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: University of Jordan
Study officials:
affiliation: Jordan University
name: Subhi M Alghanem, FFARCS
role: STUDY_CHAIR
References:
citation: Watters DA, Hollands MJ, Gruen RL, Maoate K, Perndt H, McDougall RJ, Morriss WW, Tangi V, Casey KM, McQueen KA. Perioperative mortality rate (POMR): a global indicator of access to safe surgery and anaesthesia. World J Surg. 2015 Apr;39(4):856-64. doi: 10.1007/s00268-014-2638-4.
Clinical trial NCT03402867: Effects of Dry Needling on Neck and Shoulder Pain in Orchestral Musicians: a Prospective Case Series
Official title: Effects of Myofascial Trigger Point Dry Needling on Neck Pain in Orchestral Musicians
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Pain Syndrome
Musculoskeletal Pain
Trigger Point Pain, Myofascial
Lead sponsor: CEU San Pablo University
Sponsor class: OTHER
First posted: 2018-01-18
Enrollment: 8
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Deep dry needling
Primary purpose: TREATMENT

Brief summary: This study evaluates the effectiveness of Deep dry needling of active myofascial trigger points present in muscles of the neck and shoulder region in orchestral musicians.


Eligibility criteria: Inclusion Criteria:

* Orchestral musicians
* Chronic neck or shoulder pain
* Presence of active myofascial trigger points

Exclusion Criteria:

* Fear of needles
* Coagulation disorders
* Pregnancy

Primary outcomes:
measure: Visual analogue scale for pain
timeFrame: 2 weeks
Secondary outcomes:
measure: Pressure pain threshold
timeFrame: 2 weeks
measure: Neck disability index (NDI)
timeFrame: 2 weeks
measure: Shoulder pain disability index (SPADI)
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: CEU San Pablo University
state: Comunidad De Madrid
Study officials:
References:
Clinical trial NCT02504567: Laser Ablation Study for trEatment of atRial Fibrillation (LASER)
Official title: Laser Ablation Study for trEatment of atRial Fibrillation (LASER)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Atrial Fibrillation
Keywords: Catheter Ablation
Radiofrequency
Laser
Atrial Fibrillation
Lead sponsor: Hospital Clinic of Barcelona
Sponsor class: OTHER
Collaborators: name: CardioFocus
First posted: 2015-07-22
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This protocol aims at assessing the efficacy of performing catheter ablation for atrial fibrillation (AF) with laser catheters versus performing it with radiofrequency (RF) catheters. In order to study laser catheter ablation efficacy, MRI analysis of the lesions 3 months after the procedure will be performed in both groups. MRI analysis will detect ablation gaps in the lesions encircling pulmonary veins. The primary endpoint will compare the number of gaps in the laser catheter and the RF group. The secondary endpoint of the study is recurrence of AF after 12 months. The target population of the study is patients with paroxysmal or persistent AF undergoing AF ablation.


Eligibility criteria: Inclusion Criteria:

* Patients with clinical recurrent AF, refractary or intolerant to at least 1 antiarrhythmic drub who are scheduled to undergo ablation of pulmonary veins (PV)
* Signed consent form.

Exclusion Criteria:

* Being under 18 years old
* Any contraindication for ablation procedure
* Impossibility to acquire DE-MRI because of contraindication (e.g. severely impaired renal function) or patient unwillingness

Primary outcomes:
measure: Presence of large gaps in the delayed enhancement MRI (DE-MRI)
timeFrame: 3 months
Secondary outcomes:
measure: To determine the number of patients that present atrial fibrillation after the ablation procedure
timeFrame: 1 year
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
state: Catalunya
Study officials:
References: